WASHINGTON (July 11, 2018) -- Onychomycosis, a nail fungus that causes nail disfigurement, pain, and increased risk of soft tissue infection, impacts millions of people worldwide.
There are several topical antifungal treatments currently available; however, treatment failure remains high due to a number of factors.
The most recent treatment, a broad spectrum triazole called efinaconazole, is designed to improve nail penetration.
Adam Friedman, MD, professor of dermatology at the George Washington University School of Medicine and Health Sciences, and his team investigated the use of nanotechnology to improve efinaconazole treatment and make it more cost effective.
They observed that when nitric oxide-releasing nanoparticles are combined with the efinaconazole, it achieves the same antifungal effects, but at a fraction of the amount of the medication alone needed to impart the same effect.
"Nanotechnology is being studied and employed in many areas of medicine and surgery to better deliver established imaging and therapeutic agents to ultimately improve patient outcomes," said Friedman.